SLC30A1: A Potential Drug Target for Disabilities and Neurodegenerative Disorders

Target Name: SLC30A1

NCBI ID: G7779

SLC30A1

SLC30A1: A Potential Drug Target for Disabilities and Neurodegenerative Disorders

SLC30A1 (zinc resistance conferring homolog) is a gene that has been identified as a potential drug target or biomarker for various diseases, including diabetes, cardiovascular disease, and neurodegenerative disorders. The protein encoded by this gene is involved in the regulation of zinc levels in the body, and has been shown to play a role in the development and progression of certain diseases.

SLC30A1 is a member of the SLC (sodium-dependent) transporter ATPase family, which is responsible for transporting a variety of molecules across cell membranes, including ions, nutrients, and toxins. The SLC30A1 gene is located on chromosome 11q22 and encodes a protein with 314 amino acid residues.

One of the unique features of SLC30A1 is its ability to regulate zinc levels in the body. Zinc is an essential mineral that plays a critical role in various cellular processes, including DNA replication, cell signaling, and immune function. However, too much or too little zinc can be toxic to the body, leading to a range of health problems. SLC30A1 is involved in regulating the amount of zinc that enters cells from the outside world and ensures that it is released in a controlled amount.

SLC30A1 has been shown to be involved in the development and progression of several diseases, including diabetes, cardiovascular disease, and neurodegenerative disorders. For example, studies have shown that SLC30A1 is highly expressed in the brains of individuals with Alzheimer's disease, and that it is involved in the regulation of the immune response in this disease.

In addition to its potential role in disease, SLC30A1 has also been shown to be a potential drug target. Researchers have identified several potential small molecules that can interact with the SLC30A1 protein and are being explored as potential therapeutic agents. For example, one small molecule , called ZD-101, has been shown to inhibit the activity of SLC30A1 and reduce the amount of zinc released from cells.

Another potential drug target for SLC30A1 is the interaction between SLC30A1 and the protein SLC30A2. SLC30A2 is a related protein that is also involved in the regulation of zinc levels in the body. Researchers have shown that SLC30A1 and SLC30A2 can interact with each other and that this interaction may play a role in the regulation of zinc levels in the body.

In conclusion, SLC30A1 is a gene that has been shown to be involved in the regulation of zinc levels in the body and has been identified as a potential drug target or biomarker for several diseases. Further research is needed to fully understand the role of SLC30A1 in the development and progression of these diseases and to identify safe and effective small molecules as potential therapeutic agents.

Protein Name: Solute Carrier Family 30 Member 1

Functions: Zinc ion:proton antiporter that could function at the plasma membrane mediating zinc efflux from cells against its electrochemical gradient protecting them from intracellular zinc accumulation and toxicity (PubMed:31471319). Alternatively, could prevent the transport to the plasma membrane of CACNB2, the L-type calcium channels regulatory subunit, through a yet to be defined mechanism. By modulating the expression of these channels at the plasma membrane, could prevent calcium and zinc influx into cells. By the same mechanism, could also prevent L-type calcium channels-mediated heavy metal influx into cells (By similarity). In some cells, could also function as a zinc ion:proton antiporter mediating zinc entry into the lumen of cytoplasmic vesicles. In macrophages, can increase zinc ions concentration into the lumen of cytoplasmic vesicles containing engulfed bacteria and could help inactivate them (PubMed:32441444)

The "SLC30A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC30A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets